Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fubotv Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Fubotv Inc trades at $9.84 (market cap $290.02M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 15.5× Fubotv Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FUBO | |
|---|---|---|
Market Cap | $4.49B | $290.02M |
Sector | Health | Technology |
52-Week High | $28.06 | $54.72 |
52-Week Low | $20.06 | $8.09 |
Enterprise Value | $3.69B | $460.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FUBO trades at $9.85, down 3.43% today, with a neutral technical signal. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025, representing a significant turnaround to profitability. Recent developments include streaming partnerships with NBCUniversal and the BIG3 basketball league, while analyst consensus remains positive with a $16.25 price target.
FUBO presents a compelling turnaround story with improving profitability metrics and strong analyst support, though negative cash flow and high debt levels pose execution risks. The stock offers substantial upside potential if the company can maintain its path to sustainable profitability through content partnerships and advertising growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
